Erlotinib u nemocných s nemalobuněčným karcinomem plic (NSCLC): účinný u všech podskupin nemocných i v České republice

Skřičková,  Jana; Pešek, Miloš; Kolek, Vítězslav; Salajka, František

Erlotinib u nemocných s nemalobuněčným karcinomem plic (NSCLC): účinný u všech podskupin nemocných i v České republice

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Title in English	Erlotinib in patients with non-small cell lung cancer (NSCLC). Efficacy in all patient subgroups even in the Czech Republic
Authors	SKŘIČKOVÁ Jana PEŠEK Miloš KOLEK Vítězslav SALAJKA František
Year of publication	2010
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	A multi-centre study confirms efficacy of Erlotinib in treatment of NSCLC in all subgroups of patients with non-small cell lung cancer (NSCLC). Efficacy in all patient subgroups was confirmed even in the Czech Republic
Related projects:	Environment - carcinogenesis - oncology